OptiVol® Care Pathway

NCT ID: NCT00847288

Last Updated: 2013-05-03

Study Results

Results available

Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.

View full results

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE4

Total Enrollment

1682 participants

Study Classification

INTERVENTIONAL

Study Start Date

2009-03-31

Study Completion Date

2011-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Medtronic, Inc. is sponsoring the OptiVol® Care Pathway Study, a prospective, randomized, multi-center, post-market clinical trial in the United States. The purpose of this clinical trial is to compare monthly versus quarterly review of Cardiac Compass® Trends with OptiVol for initiation of clinical action. It is hypothesized that monthly review of Cardiac Compass Trends with OptiVol will shorten time to clinical action as compared to quarterly review.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Heart Failure

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Monthly Review Arm

Patients enrolled at centers that are assigned to the monthly review arm will have their device data reviewed monthly

Group Type EXPERIMENTAL

Monthly Review Arm

Intervention Type OTHER

Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.

Quarterly Review Arm

Patients enrolled at centers that are assigned to the quarterly review arm will have their device data reviewed every 3 months

Group Type ACTIVE_COMPARATOR

Quarterly Review Arm

Intervention Type OTHER

Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Monthly Review Arm

Monthly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.

Intervention Type OTHER

Quarterly Review Arm

Quarterly review of Cardiac Compass Trends with OptiVol. This intervention is related to disease management.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subject (or subject's legally authorized representative) is willing and able to sign and date written consent form and Authorization for Access to and Use of Health Information
* Subject is at least 18 years of age
* Subject is willing and able to comply with Clinical Investigation Plan
* Subject is willing and able to transmit data using Medtronic CareLink® Network
* Subject has market released right atrial (RA) (if applicable), right ventricular (RV), and left ventricular (LV) (if applicable) leads and one of the following generators implanted: Concerto® CRT-D - Model C154DWK, Virtuoso® DR ICD - Model D154AWG, Virtuoso® VR ICD - Model D154VWC, Consulta™ CRT-D - Model D224TRK, Secura™ DR ICD - Model D224DRG, Secura™ VR ICD - Model D224VRC, or any future market released Medtronic generator with wireless telemetry, Cardiac Compass with OptiVol Fluid Status Monitoring, and that is supported by the Medtronic CareLink Network

Exclusion Criteria

* Subject is enrolled in a concurrent study with the exception of a study approved by the Medtronic Clinical Trial Leader prior to enrollment
* Subject has life expectancy of less than 1 year
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Medtronic Cardiac Rhythm and Heart Failure

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Wilson Tang, MD

Role: PRINCIPAL_INVESTIGATOR

Department of Cardiovascular Medicine, Cleveland Clinic

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Birmingham, Alabama, United States

Site Status

Mobile, Alabama, United States

Site Status

Anchorage, Alaska, United States

Site Status

Mesa, Arizona, United States

Site Status

Fort Smith, Arkansas, United States

Site Status

Little Rock, Arkansas, United States

Site Status

Alhambra, California, United States

Site Status

Berkeley, California, United States

Site Status

Burbank, California, United States

Site Status

Chula Vista, California, United States

Site Status

La Jolla, California, United States

Site Status

Larkspur, California, United States

Site Status

Pomona, California, United States

Site Status

Rancho Mirage, California, United States

Site Status

Riverside, California, United States

Site Status

San Francisco, California, United States

Site Status

Torrance, California, United States

Site Status

Boulder, Colorado, United States

Site Status

Colorado Springs, Colorado, United States

Site Status

Brandenton, Florida, United States

Site Status

Clearwater, Florida, United States

Site Status

Daytona Beach, Florida, United States

Site Status

Fort Lauderdale, Florida, United States

Site Status

Gainesville, Florida, United States

Site Status

Inverness, Florida, United States

Site Status

Jacksonville, Florida, United States

Site Status

Jupiter, Florida, United States

Site Status

Miami, Florida, United States

Site Status

Orlando, Florida, United States

Site Status

Trinity, Florida, United States

Site Status

Augusta, Georgia, United States

Site Status

Columbus, Georgia, United States

Site Status

Chicago, Illinois, United States

Site Status

Kankakee, Illinois, United States

Site Status

Oak Lawn, Illinois, United States

Site Status

Rockford, Illinois, United States

Site Status

Bloomington, Indiana, United States

Site Status

Muncie, Indiana, United States

Site Status

Munster, Indiana, United States

Site Status

Terre Haute, Indiana, United States

Site Status

Davenport, Iowa, United States

Site Status

Des Moines, Iowa, United States

Site Status

Ashland, Kentucky, United States

Site Status

Lexington, Kentucky, United States

Site Status

Louisville, Kentucky, United States

Site Status

Shreveport, Louisiana, United States

Site Status

Bangor, Maine, United States

Site Status

Glen Burnie, Maryland, United States

Site Status

Rockville, Maryland, United States

Site Status

Salisbury, Maryland, United States

Site Status

Boston, Massachusetts, United States

Site Status

Detroit, Michigan, United States

Site Status

Grand Blanc, Michigan, United States

Site Status

Grand Rapids, Michigan, United States

Site Status

Petosky, Michigan, United States

Site Status

Sterling Heights, Michigan, United States

Site Status

Coon Rapids, Minnesota, United States

Site Status

Minneapolis, Minnesota, United States

Site Status

Saint Cloud, Minnesota, United States

Site Status

Columbia, Missouri, United States

Site Status

Kansas City, Missouri, United States

Site Status

Saint Joseph, Missouri, United States

Site Status

Springfield, Missouri, United States

Site Status

St Louis, Missouri, United States

Site Status

Omaha, Nebraska, United States

Site Status

Reno, Nevada, United States

Site Status

Bridgewater, New Jersey, United States

Site Status

Galloway, New Jersey, United States

Site Status

Newark, New Jersey, United States

Site Status

Ocean City, New Jersey, United States

Site Status

Voorhees Township, New Jersey, United States

Site Status

Buffalo, New York, United States

Site Status

Fayetteville, New York, United States

Site Status

Garden City, New York, United States

Site Status

Durham, North Carolina, United States

Site Status

Gastonia, North Carolina, United States

Site Status

Greensboro, North Carolina, United States

Site Status

Wilmington, North Carolina, United States

Site Status

Minot, North Dakota, United States

Site Status

Akron, Ohio, United States

Site Status

Cleveland, Ohio, United States

Site Status

Kettering, Ohio, United States

Site Status

Poland, Ohio, United States

Site Status

Steubenville, Ohio, United States

Site Status

Toledo, Ohio, United States

Site Status

Oklahoma City, Oklahoma, United States

Site Status

Bend, Oregon, United States

Site Status

Doylestown, Pennsylvania, United States

Site Status

Lancaster, Pennsylvania, United States

Site Status

Philadelphia, Pennsylvania, United States

Site Status

Pittsburgh, Pennsylvania, United States

Site Status

Wynnewood, Pennsylvania, United States

Site Status

Columbia, South Carolina, United States

Site Status

Greenwood, South Carolina, United States

Site Status

Spartanburg, South Carolina, United States

Site Status

West Columbia, South Carolina, United States

Site Status

Germantown, Tennessee, United States

Site Status

Johnson City, Tennessee, United States

Site Status

Memphis, Tennessee, United States

Site Status

Nashville, Tennessee, United States

Site Status

Austin, Texas, United States

Site Status

Corpus Christi, Texas, United States

Site Status

McAllen, Texas, United States

Site Status

San Antonio, Texas, United States

Site Status

Tyler, Texas, United States

Site Status

Lynchburg, Virginia, United States

Site Status

Spokane, Washington, United States

Site Status

Madison, Wisconsin, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

OptiVol® Care Pathway

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

PROACTIVE-HF IDE Trial Heart Failure NYHA Class III
NCT04089059 ACTIVE_NOT_RECRUITING NA
CARE-HF Long Term Follow-up
NCT00318357 COMPLETED